ArticleEye (London, England)2026
Regional variation and trends in prostaglandin analogue prescribing for glaucoma in England 2019-2024.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrescribing for glaucoma drops constitutes a large proportion of the NHS medicines budget for ophthalmology. NICE guidelines direct clinicians towards the prescription of a generic prostaglandin analogue (PGA) as a first-line topical hypotensive for lowering intraocular pressure. Between 2009 and 2018 the cost-effectivity of PGA prescribing at a national level in England was questionable. This study aimed to examine the variation and trends of PGA prescription at a regional level from 2019 to 2024.
methodsUsing an online open-access source, monthly data relating to General Practitioner prescription of latanoprost, bimatoprost, travoprost and tafluprost were collected. Data gathered related to PGA prescription activity from each of the individual Clinical Commissioning Groups (CCGs) in England. Descriptive statistics and choropleth maps were produced to display outcomes.
resultsTotal PGA prescribing cost over 5 years was £166 M for 21.9 M prescriptions. A broad trend towards generic prescribing was identified. Branded and preservative free prescribing, in preference to a generic equivalent, resulted in an additional cost of approximately £54 M. Latanoprost was most readily prescribed in the South West and South East regions. Bimatoprost and travoprost were prescribed more in the North East and the East of England respectively.
conclusionsRegional variation in PGA prescribing exists in England. Further investigation is required to determine the primary cause for the reported differences. Reducing variations so that prescribing clinicians are directed towards the most cost-effective PGA choice has the potential for considerable cost savings to NHS budgets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.